GT Biopharma (GTBP) Total Current Liabilities (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Total Current Liabilities of $2.4 million for Q1 2026, down 33.59% year-over-year from $3.6 million in Q1 2025, and up 4.18% quarter-over-quarter from $2.3 million in Q4 2025.
GT Biopharma (GTBP) Total Current Liabilities (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Total Current Liabilities for 17 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 33.59% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 33.59% YoY), while the FY2025 annual figure was $2.3 million, down 60.71% from the prior year.
- Total Current Liabilities advanced to $2.4 million in Q1 2026 per GTBP's latest filing, from $2.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $31.0 million in Q2 2025 and bottomed at $1.3 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $6.5 million across 5 years, with a median of $4.9 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 162.82% — and 2025, when it plunged 71.66%.
- GT Biopharma's Total Current Liabilities stood at $4.9 million in 2022, then soared by 34.33% to $6.6 million in 2023, then slipped by 11.02% to $5.9 million in 2024, then sank by 60.71% to $2.3 million in 2025, then gained by 4.18% to $2.4 million in 2026.
- Business Quant data shows GTBP's Total Current Liabilities at $2.4 million in Q1 2026, $2.3 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 2.32 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 31.04 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Mar 31, 2024 | 4.60 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Sep 30, 2023 | 5.09 Mn |
| Jun 30, 2023 | 4.84 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 4.94 Mn |
| Sep 30, 2022 | 5.03 Mn |
| Jun 30, 2022 | 8.61 Mn |
| Mar 31, 2022 | 9.50 Mn |
| Dec 31, 2021 | 10.26 Mn |
| Sep 30, 2021 | 3.92 Mn |
| Jun 30, 2021 | 3.28 Mn |
| Mar 31, 2021 | 3.63 Mn |